ASCO 2023 | 24 month OS results of the SCANDIUM trial

Roger Olofsson Bagge, MD, PhD, Gothenburg University, Gothenburg, Sweden, discusses findings from the Phase III SCANDIUM trial (NCT01785316) of isolated hepatic perfusion (IHP) in patients with liver metastases of uveal melanoma. Previous data have demonstrated IPH to result in superior response rate and progression-free survival compared to the standard of care. Patients receiving IHP additionally had longer overall survival at 24 months, but was not statistically significant. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.